Literature DB >> 22175655

Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS.

D Eldon Spackman1, Srikanth Kadiyala, Peter J Neumann, David L Veenstra, Sean D Sullivan.   

Abstract

OBJECTIVES: Estimate the probabilities, for Alzheimer's disease (AD) patients, of transitioning between stages of disease severity (mild, moderate, severe, dead) and care settings (community, institutional).
METHODS: Data were compiled by the National Alzheimer Coordinating Center. The main analyses were limited to 3,852 patients who were 50 years old, diagnosed with possible/probable AD and had at least two center visits. A multinomial logistic model accounting for patient and center level correlation was used to calculate transition probabilities between stages of the Clinical Dementia Rating (CDR). Separately we calculated the probabilities of being institutionalized based on CDR stage. Both analyses controlled for baseline age, time between visits, sex, marital status, whether white, whether Hispanic and number of years of education.
RESULTS: The annual probabilities of dying for patients in mild, moderate and severe health states were 5.5%, 21.5% and 48.0%, respectively, while the annual probabilities for institutionalization were 1.2%, 3.4% and 6.6%, respectively. The majority of mild and moderate patients remain in the same health state after one year, 77.4% and 50.1% respectively. Progressing patients are most likely to transition one stage, but 1.3% of mild patients become severe in one year. Some patients revert to lower severity stages, 7% from moderate to mild.
CONCLUSIONS: Transition probabilities to higher CDR stages and to institutionalization are lower than those published previously, but the probability of death is higher. These results are useful for understanding AD progression and can be used in simulation models to evaluate costs and compare new treatments or policies.

Entities:  

Mesh:

Year:  2012        PMID: 22175655      PMCID: PMC3690579          DOI: 10.2174/156720512803569046

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  32 in total

1.  Home or nursing home: does place of residence affect longevity in patients with Alzheimer's disease? The experience of CERAD patients.

Authors:  Bercedis L Peterson; Gerda G Fillenbaum; Carl F Pieper; Albert Heyman
Journal:  Public Health Nurs       Date:  2008 Sep-Oct       Impact factor: 1.462

2.  Survival in Alzheimer disease: a multiethnic, population-based study of incident cases.

Authors:  E P Helzner; N Scarmeas; S Cosentino; M X Tang; N Schupf; Y Stern
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

3.  Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.

Authors:  Howard H Feldman; Tuula Pirttila; Jean François Dartigues; Brian Everitt; Bart Van Baelen; Susanne Schwalen; Shane Kavanagh
Journal:  Int J Geriatr Psychiatry       Date:  2009-05       Impact factor: 3.485

4.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.

Authors:  O L Lopez; J T Becker; A S Wahed; J Saxton; R A Sweet; D A Wolk; W Klunk; S T Dekosky
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-09       Impact factor: 10.154

5.  The effects of counseling spouse caregivers of people with Alzheimer disease taking donepezil and of country of residence on rates of admission to nursing homes and mortality.

Authors:  Henry Brodaty; Mary Mittelman; Louisa Gibson; Katrin Seeher; Alistair Burns
Journal:  Am J Geriatr Psychiatry       Date:  2009-09       Impact factor: 4.105

6.  Race/ethnic differences in AD survival in US Alzheimer's Disease Centers.

Authors:  K M Mehta; K Yaffe; E J Pérez-Stable; A Stewart; D Barnes; B F Kurland; B L Miller
Journal:  Neurology       Date:  2007-11-14       Impact factor: 9.910

7.  Recent trends in Alzheimer disease mortality in the United States, 1999 to 2004.

Authors:  Kyle Steenland; Jessica MacNeil; Irving Vega; Allan Levey
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

8.  Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.

Authors:  David L Sultzer; Sonia M Davis; Pierre N Tariot; Karen S Dagerman; Barry D Lebowitz; Constantine G Lyketsos; Robert A Rosenheck; John K Hsiao; Jeffrey A Lieberman; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2008-06-02       Impact factor: 18.112

9.  Stability of the Clinical Dementia Rating, 1979-2007.

Authors:  Monique M Williams; Catherine M Roe; John C Morris
Journal:  Arch Neurol       Date:  2009-06

Review 10.  Systematic review of the effect of education on survival in Alzheimer's disease.

Authors:  Matt Paradise; Claudia Cooper; Gill Livingston
Journal:  Int Psychogeriatr       Date:  2008-11-25       Impact factor: 3.878

View more
  23 in total

1.  Antipsychotic Use in a Diverse Population With Dementia: A Retrospective Review of the National Alzheimer's Coordinating Center Database.

Authors:  Glen L Xiong; Teresa Filshtein; Laurel A Beckett; Ladson Hinton
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2015       Impact factor: 2.198

2.  Deep brain stimulation for Alzheimer disease: a decision and cost-effectiveness analysis.

Authors:  Keyvan Mirsaeedi-Farahani; C H Halpern; G H Baltuch; D A Wolk; S C Stein
Journal:  J Neurol       Date:  2015-03-06       Impact factor: 4.849

3.  SPIRIT advance care planning intervention in early stage dementias: An NIH stage I behavioral intervention development trial.

Authors:  Mi-Kyung Song; Sandra E Ward; Kenneth Hepburn; Sudeshna Paul; Raj C Shah; Darby J Morhardt
Journal:  Contemp Clin Trials       Date:  2018-06-02       Impact factor: 2.226

4.  Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.

Authors:  Matthew Davis; Thomas O Connell; Scott Johnson; Stephanie Cline; Elizabeth Merikle; Ferenc Martenyi; Kit Simpson
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

5.  Analyzing Individual-Level Secondary Data with Instrumental Variable Methods Is Useful for Studying the Effects of Air Pollution on Dementia.

Authors:  Kelly C Bishop; Sehba Husain-Krautter; Jonathan D Ketcham; Nicolai V Kuminoff; Corbett Schimming
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

6.  Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.

Authors:  Eric L Ross; Marc S Weinberg; Steven E Arnold
Journal:  JAMA Neurol       Date:  2022-05-01       Impact factor: 29.907

7.  Modeling test and treatment strategies for presymptomatic Alzheimer disease.

Authors:  James F Burke; Kenneth M Langa; Rodney A Hayward; Roger L Albin
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

8.  Predicting the progression of Alzheimer's disease dementia: A multidomain health policy model.

Authors:  Colin Green; Shenqiu Zhang
Journal:  Alzheimers Dement       Date:  2016-03-24       Impact factor: 21.566

9.  Learning Biomarker Models for Progression Estimation of Alzheimer's Disease.

Authors:  Alexander Schmidt-Richberg; Christian Ledig; Ricardo Guerrero; Helena Molina-Abril; Alejandro Frangi; Daniel Rueckert
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

10.  The development of a stochastic mathematical model of Alzheimer's disease to help improve the design of clinical trials of potential treatments.

Authors:  Christoforos Hadjichrysanthou; Alison K Ower; Frank de Wolf; Roy M Anderson
Journal:  PLoS One       Date:  2018-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.